Orforglipron Demonstrates Superior HbA1c Reduction Over Oral Semaglutide in Type 2 Diabetes: Results from the ACHIEVE-3 Trial

Highlights

• Orforglipron (12 mg and 36 mg) achieved statistically superior HbA1c reductions compared to both 7 mg and 14 mg doses of oral semaglutide over 52 weeks.
• As a non-peptide GLP-1 receptor agonist, orforglipron simplifies treatment by removing food and water restrictions associated with current oral peptide therapies.
• The superior efficacy was accompanied by a higher incidence of gastrointestinal adverse events and a higher rate of treatment discontinuation compared to oral semaglutide.
• Mean pulse rate increases were more pronounced in the orforglipron treatment arms.

Background: The Evolution of Oral Incretin Therapies

The management of type 2 diabetes (T2D) has been significantly advanced by the development of glucagon-like peptide-1 (GLP-1) receptor agonists. While injectable formulations have dominated the market, oral options offer a more convenient route for patients, potentially improving adherence and early initiation of therapy. Oral semaglutide, a peptide-based agonist, currently requires strict administration protocols, including fasting and limited water intake, to ensure adequate absorption. Orforglipron, a novel non-peptide GLP-1 receptor agonist, represents a pharmacological shift. Its non-peptide structure is designed for daily oral administration without the stringent dietary restrictions that complicate current oral peptide therapies.

The ACHIEVE-3 trial was designed to evaluate whether this new class of non-peptide agonists could match or exceed the efficacy and safety of the current standard in oral GLP-1 therapy. This multinational, multicentre study specifically focused on individuals whose type 2 diabetes remained inadequately controlled despite metformin therapy.

Study Design and Methodology: The ACHIEVE-3 Framework

ACHIEVE-3 was a 52-week, randomised, open-label, active-controlled, phase 3 trial. The study enrolled 1,698 adults from 131 research centres across Argentina, China, Japan, Mexico, and the USA. Eligible participants had a baseline HbA1c between 7.0% and 10.5%, a BMI of at least 25 kg/m2, and were on a stable dose of metformin (at least 1500 mg per day).

Randomisation and Interventions

Participants were randomly assigned in a 1:1:1:1 ratio to receive either orforglipron (12 mg or 36 mg) or oral semaglutide (7 mg or 14 mg). The trial included a 4-week lead-in period followed by a 52-week treatment phase. All medications were administered orally once per day.

Endpoints and Statistical Analysis

The primary objective was to establish the non-inferiority of orforglipron (36 mg vs semaglutide 14 mg and 12 mg vs semaglutide 7 mg) regarding the mean change in HbA1c from baseline to week 52. The non-inferiority margin was set at 0.3%. A hierarchical analysis was pre-specified to test for superiority once non-inferiority was confirmed. The primary estimand was the treatment regimen estimand, which includes data from all participants regardless of adherence or intercurrent events, reflecting real-world clinical outcomes.

Key Findings: Superiority in Glycemic Control

The results of the ACHIEVE-3 trial indicate that orforglipron is not only non-inferior but also superior to oral semaglutide in lowering glycated haemoglobin (HbA1c) levels in this patient population.

HbA1c Reductions at Week 52

At the 52-week mark, the mean changes from a baseline HbA1c of 8.3% were as follows:

• Orforglipron 12 mg: -1.71% (SE 0.07)
• Orforglipron 36 mg: -1.91% (SE 0.08)
• Semaglutide 7 mg: -1.23% (SE 0.05)
• Semaglutide 14 mg: -1.47% (SE 0.06)

Treatment Differences and Statistical Significance

The estimated treatment differences (ETD) confirmed superiority across the primary comparison groups:

• Orforglipron 12 mg vs Semaglutide 7 mg: -0.48% (95% CI -0.65 to -0.31; p < 0.0001)
• Orforglipron 36 mg vs Semaglutide 14 mg: -0.44% (95% CI -0.62 to -0.26; p < 0.0001)

Furthermore, even the lower dose of orforglipron (12 mg) demonstrated superiority over the higher dose of oral semaglutide (14 mg), with an ETD of -0.24% (95% CI -0.41 to -0.072; p = 0.0050). The comparison between orforglipron 36 mg and semaglutide 7 mg showed the largest gap, with an ETD of -0.68% (95% CI -0.85 to -0.50; p < 0.0001).

Safety and Tolerability: Navigating the GI Challenge

While orforglipron demonstrated clear advantages in efficacy, the safety profile highlighted specific areas of concern common to the GLP-1 receptor agonist class, albeit with higher frequency in the orforglipron cohorts.

Gastrointestinal Adverse Events

Gastrointestinal (GI) events were the most frequently reported adverse effects. These were noted in 59% of the orforglipron 12 mg group and 58% of the 36 mg group, compared to 37% and 45% in the semaglutide 7 mg and 14 mg groups, respectively. Most events were characterized as mild to moderate in severity, but they contributed to higher discontinuation rates. Approximately 9-10% of participants in the orforglipron groups discontinued treatment due to adverse events, compared to 4-5% in the semaglutide groups.

Pulse Rate and Mortality

A notable finding was the mean increase in pulse rate, which was higher in the orforglipron groups (3.7 bpm for 12 mg and 4.7 bpm for 36 mg) than in the semaglutide groups (1.0 bpm for 7 mg and 1.5 bpm for 14 mg). Regarding mortality, four deaths occurred during the study period: one in each orforglipron dose group and two in the semaglutide 7 mg group. These deaths were not considered related to the study medications by investigators.

Expert Commentary: Clinical Implications of Non-Peptide Agonists

The ACHIEVE-3 results suggest that orforglipron could redefine the role of oral incretin therapy. The ability to achieve HbA1c reductions of nearly 2% with an oral agent is substantial and rivals many injectable therapies. Perhaps more importantly, the lack of food and water restrictions addresses a major barrier to patient adherence seen with oral peptide-based GLP-1 RAs.

However, clinicians must weigh these benefits against the increased GI burden. The higher discontinuation rates suggest that titration strategies or patient selection may need to be refined as orforglipron moves toward clinical use. The pulse rate increase, while consistent with the class effect of GLP-1 RAs, was more pronounced with orforglipron and warrants further investigation into long-term cardiovascular outcomes.

Conclusion: A New Chapter in Oral T2D Management

Orforglipron represents a potent and potentially more flexible oral treatment option for adults with type 2 diabetes. By demonstrating superiority over the current oral gold standard, semaglutide, orforglipron proves that non-peptide agonists can deliver high-level glycemic control. While the gastrointestinal tolerability profile requires careful management, the efficacy data from ACHIEVE-3 positions orforglipron as a major future contender in the metabolic disease landscape.

Funding and ClinicalTrials.gov

This study was funded by Eli Lilly. The trial is registered with ClinicalTrials.gov, number NCT06045221.

References

1. Rosenstock J, Yabe D, Cox D, et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet. 2026 Feb 26:S0140-6736(26)00202-3.
2. Knop FK, Aroda VR, Doerhing RU, et al. Oral semaglutide and the evolution of GLP-1 receptor agonists. Expert Opinion on Drug Metabolism & Toxicology. 2022;18(10):651-661.